Neptune Krill Oil Proven Effective for Cholesterol
Monday, January 24 2005

Neptune Krill Oil NKO™ Proven Effective for Cholesterol
Regulation: "Alternative Medicine Review"

MONTREAL, Jan. 24, 2005 /CNW Telbec/ - Neptune Technologies & Bioressources Inc. is pleased to announce that Alternative Medicine Review, recently published, in December 2004, its 2nd NKO™ research, a conclusive clinical trial on the effects of Neptune Krill Oil NKO™ on cholesterol (hyperlipidemia); in the USA alone, it afflicts over 100 million people, titled "Evaluation of the Effects of Neptune Krill Oil on the Clinical Course of Hyperlipidemia." The well known medical journal available in the USA, New Zealand, Australia and Europe, reaching more than 8,000 medical doctors, health care practitioners, pharmacies and medical libraries and one of the most recognized peer-reviewed publications in the nutraceutical industry. The previous clinical research published in the July 2003 issue, summarized the huge benefits of NKO™ for premenstrual syndrome (PMS).

"The results of the present study clearly demonstrate, within high levels of confidence, that NKO™ is effective for the management of hyperlipidemia by significantly reducing total cholesterol, LDL (bad cholesterol) and triglycerides, and increasing HDL (good cholesterol). At one third the dosage, NKO™ was not only more effective than fish oil, in reducing LDL, but also in increasing, significantly more, HDL," commented Dr. Tina Sampalis, Vice-President of Research & Development, at Neptune Technologies & Bioressources Inc. "The results of this trial prove that NKO™ is a safe, effective and among the best alternative products for the regulation of blood lipids, without the side-effects and high dose requirements of fish oil. Once again, NKO™ demonstrates the superior effectiveness of its patented novel molecules". "In this turbulent time of continuous announcements of drug sideeffects, the unique and effective molecular structure of NKO™ is triggering the interest of giants in the Health Industry", added Dr. Sampalis.

Neptune Technologies & Bioressources Inc. develops and exploits marine biomasses with its patented extraction process Neptune OceanExtract™ utilizing marine biomasses, such as krill, and due to its technologies, Neptune Technologies & Bioressources Inc., is strategically well positioned in the $182 billion global nutrition market (Nutrition Business Journal, Oct/Nov 2004) based on the health and wellness concepts, markets in which natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the adequacy or accuracy of this press release.
Neptune Technologies and Acasti Pharma Contact:
Neptune Technologies & Bioressources Inc.
Acasti Pharma Inc.
Toni Rinow, Ph.D., MBA
Corporate Development & Investor Relations
(450) 687-2262
This e-mail address is being protected from spambots, you need JavaScript enabled to view it
# # #
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.
 

We communicate

NTB (TSX) CAN$ 1.93 +0.03
NEPT (NASDAQ) US$ 1.898 +0.068
 

press releases

Investor Relations Contact NEPTUNE TECHNOLOGIES & BIORESSOURCES